Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293521 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBNPC1EPHX2 | |
| SCHEMBL292431 | 0.84 | ALDH1A1 (0.58) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL292429 | 0.84 | ALDH1A1 (0.58) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL291869 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL291871 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL291745 | 0.82 | ALDH1A1 (0.52) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL291743 | 0.82 | ALDH1A1 (0.52) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL291393 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL291395 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBNPC1PKM | |
| SCHEMBL292637 | 0.80 | ALDH1A1 (0.50) | ALDH1A1LMNAPOLBNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | ALDH1A1 1293/4885LMNA 1720/4885POLB 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.